Variable | No. of patients n = 167 | |
---|---|---|
Bone marrow CD138+ plasma cells n = 167 | Peripheral blood plasma n = 69 | |
Disease | ||
sMM | 28 (16.8%) | – |
MM | 139 (83.2%) | 69 (100.0%) |
Multiple myeloma patients | ||
R-ISS stage | ||
R-ISS I | 34 (24.5%) | 20 (29.0%) |
R-ISS II | 68 (48.9%) | 28 (40.6%) |
R-ISS III | 28 (20.1%) | 14 (20.3%) |
No data | 9 | 7 |
ISS Stage | ||
ISS I | 40 (28.8%) | 25 (36.2%) |
ISS II | 43 (30.9%) | 19 (27.5%) |
ISS III | 55 (39.6%) | 24 (34.8%) |
No data | 1 | 1 |
Gender | ||
Male | 77 (55.4%) | 38 (55.1%) |
Female | 62 (44.6%) | 31 (44.9%) |
Therapy | ||
Bortezomib-based regimens | 122 (87.8%) | 65 (94.2%) |
Lenalidomide-dexamethasone | 12 (8.6%) | 4 (5.8%) |
Other | 2 (1.4%) | 0 |
Not complete treatment | 3 (2.2%) | 0 |
Bone disease | ||
Yes | 92 (66.2%) | 42 (60.9%) |
No | 38 (27.3%) | 27 (39.1%) |
No data | 9 | 0 |
HDM/ASCT | ||
Yes | 38 (27.3%) | 28 (40.6%) |
No | 100 (71.9%) | 41 (59.4%) |
No data | 1 | 0 |
B2M | ||
< 3.5 mg/l | 43 (30.9%) | 26 (37.7%) |
≥ 3.5 mg/l and < 5.5 mg/l | 41 (29.5%) | 19 (27.5%) |
> 5.5 mg/l | 54 (38.8%) | 23 (33.3%) |
No data | 1 | 1 |
LDH | ||
≤ 220 U/l | 107 (77.0%) | 54 (78.3%) |
> 220 U/l | 32 (23.0%) | 15 (21.7%) |
Marrow plasma cells | ||
< 60% | 58 (41.7%) | 33 (47.8%) |
≥ 60% | 81 (58.3%) | 36 (52.2%) |
Response to 1st line | ||
sCR / CR / VGPR | 90 (64.7%) | 47 (68.1%) |
PR / SD / PD | 45 (32.4%) | 22 (30.4%) |
No data | 4 | 0 |
Disease monitoring | ||
Follow-up patients | 135 | 69 |
Relapse | 33 (24.4%) | 17 (24.6%) |
Death | 30 (22.2%) | 13 (18.8%) |
Progression | 49 (36.3%) | 25 (36.2%) |
Excluded from follow-up | 4 | 0 |